[CAS NO. 1405-86-3] Glycyrrhizic acid

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [1405-86-3]

Catalog

HY-N0184

Brand

MCE

CAS

1405-86-3

DESCRIPTION [1405-86-3]

Overview

MDL	-
Molecular Weight	822.93
Molecular Formula	C42H62O16
SMILES	C[C@]12[C@@](C(C=C3[C@]2(CC[C@]4(C)[C@@]3([H])C[C@](C(O)=O)(C)CC4)C)=O)([H])[C@@]5([C@@](C(C)([C@@H](O[C@]6([H])[C@@H]([C@H]([C@H](O)[C@@H](C(O)=O)O6)O)O[C@]7([H])O[C@@H]([C@@H](O)[C@H](O)[C@H]7O)C(O)=O)CC5)C)([H])CC1)C

For research use only. We do not sell to patients.

15 Publications Citing Use of MCE

Summary

Glycyrrhizic acid is a triterpenoid saponinl, acting as a direct HMGB1 antagonist, with anti-tumor, anti-diabetic activities.

In Vitro

Glycyrrhizic acid shows a series of anti-cancer-related pharmacological activities, such as broad-spectrum anti-cancer ability, resistance to the tissue toxicity caused by chemotherapy and radiation, drug absorption enhancing effects and anti-multidrug resistance (MDR) mechanisms, as a carrier material in drug delivery systems ^[1] .
In intestinal NCI-H716 cells that secretes GLP-1, Glycyrrhizic acid promotes GLP-1 secretion with a marked elevation of calcium levels. Glycyrrhizic acid can enhance GLP-1 secretion through TGR5 activation ^[2] .
Glycyrrhizic acid can form a stable transparent low-molecular-weight hydrogels (LMWHs) at 37°C in physiological phosphate buffered saline (PBS) with nanoclusters as the microstructures ^[4] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

In type 1-like diabetic rats induced by streptozotocin (STZ-treated rats), Glycyrrhizic acid increases the level of plasma GLP-1, which is blocked by triamterene at a dose sufficient to inhibit Takeda G-protein-coupled receptor 5 (TGR5) ^[1] . Glycyrrhizic acid (Glycyrrhizic acid; 50 mg/kg, i.p.) significantly decreases the levels of TgAb, HMGB1, TNF-α, IL-6, IL-1β in mice ^[3] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT04028869	Beijing Ditan Hospital	Autoimmune Liver Disease	March 1, 2018
NCT04742660	Konkuk University Medical Center	Postoperative Nausea	May 11, 2021	Not Applicable
NCT05276895	Assiut University	Osteoarthritis	December 1, 2022	Not Applicable

Appearance

Solid

Source

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : 500 mg/mL ( 607.59 mM ; Need ultrasonic)

H ₂ O : < 0.1 mg/mL (insoluble)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	1.2152 mL	6.0759 mL	12.1517 mL
5 mM	0.2430 mL	1.2152 mL	2.4303 mL
10 mM	0.1215 mL	0.6076 mL	1.2152 mL

* Please refer to the solubility information to select the appropriate solvent.

In Vivo:

1.

Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline

Solubility: ≥ 22.5 mg/mL (27.34 mM); Clear solution
2.

Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)

Solubility: 10 mg/mL (12.15 mM); Suspended solution; Need ultrasonic
3.

Add each solvent one by one: 10% DMSO >> 90% corn oil

Solubility: 10 mg/mL (12.15 mM); Suspended solution; Need ultrasonic

* All of the co-solvents are available by MCE.

References

Synonyms

α-D-Glucopyranosiduronic acid, (3β,20β)-20-carboxy-11-oxo-30-norolean-12-en-3-yl 2-O-β-D-glucopyranuronosyl-

Glycyrrhizic acid

30-Noroleanane, α-D-glucopyranosiduronic acid deriv.

(3β,20β)-20-Carboxy-11-oxo-30-norolean-12-en-3-yl 2-O-β-D-glucopyranuronosyl-α-D-glucopyranosiduronic acid

Glycyrrhizin

Glycyrrhizinic acid

Glycyrrhetinic acid glycoside

Glycyron

β-Glycyrrhizin

18β-Glycyrrhizic acid

Potenlini

NSC 167409

NSC 234419

18β-Glycyrrhizinic acid

Gancaotiansu